{"id":159362,"date":"2010-01-09T17:15:07","date_gmt":"2010-01-09T22:15:07","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=57873"},"modified":"2010-01-09T17:15:07","modified_gmt":"2010-01-09T22:15:07","slug":"alder-rival-wins-fda-approval","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/159362","title":{"rendered":"Alder Rival Wins FDA Approval"},"content":{"rendered":"\n
Biotech<\/a>, Rheumatoid Arthritis<\/a>, Drugs<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

[Correction: 1\/11\/10, 9:15 am Pacific, with distinction between IL-6 and IL-6 receptor.<\/em>] Genentech, the U.S.-based unit of Swiss pharmaceutical giant Roche, said<\/a> the FDA has granted clearance to start selling a new drug for rheumatoid arthritis. The treatment, tocilizumab (Actemra), is the first approved antibody engineered to block the receptor for an inflammatory protein called IL-6, that is overactive in patients with rheumatoid arthritis. Bothell, WA-based Alder Biopharmaceuticals is attempting to block the IL-6 protein with a “fast-follower<\/a>” antibody called ALD518, which is being co-developed with Bristol-Myers Squibb<\/a>.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, Rheumatoid Arthritis, Drugs Luke Timmerman wrote: [Correction: 1\/11\/10, 9:15 am Pacific, with distinction between IL-6 and IL-6 receptor.] Genentech, the U.S.-based unit of Swiss pharmaceutical giant Roche, said the FDA has granted clearance to start selling a new drug for rheumatoid arthritis. The treatment, tocilizumab (Actemra), is the first approved antibody engineered to block […]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-159362","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/159362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=159362"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/159362\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=159362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=159362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=159362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}